The Clorox Company -- 4.8/10 -- $101.14

AVOID / WATCHLIST

NYSE: CLX | Household cleaning and wellness company with dominant positions in bleach, charcoal, trash bags, and cat litter. Down 33% from 52-week highs near $151, trading at $101 with a 4.9% dividend yield and RSI of 31.8 approaching oversold. Revenue has gone nowhere in 5 years. FY2026 H1 shows sharp deterioration across margins and EPS from ERP transition disruption. Sentiment score of 7 suggests contrarian setup, but weak financials (4) and thematics (4) keep the composite below the threshold.

FY2025 Revenue

$7.1B

Flat YoY | lower than FY2021 ($7.3B)

Adj. EBIT Margin (FY2025)

18.5%

+370bps from FY22 trough | margin recovery complete

GAAP EPS (TTM)

$6.13

FY26 H1 deteriorating: $0.65 + $1.29

Composite Score

4.8 / 10

AVOID - Below 6 threshold

Quality gate results

Oligopoly / Dominant Position

MIXED

Kingsford ~80% charcoal share, Clorox ~60% bleach share, Glad ~30-35% branded trash bags. Over 80% of revenue from #1 or #2 category positions. But dominant shares are in mature, low-growth, commodity-adjacent categories with 0-1% underlying growth. Oligopoly provides defense, not offense.

Positive and Growing FCF

YES (VOLATILE)

FY2025 FCF of $761M (10.7% of sales), recovering from $483M in FY2024. But highly volatile: FQ1 FY2026 FCF collapsed to $57M vs $182M prior year. FQ2 FY2026 rebounded to $269M. Dividend well covered at 4.9% yield but FCF trajectory is inconsistent.

Management 3+ Year Track Record

PARTIAL

CEO Linda Rendle (since Sep 2020) delivered impressive gross margin rebuild from 35.8% to 45.2% over 3 years. But IGNITE 3-5% organic growth algorithm never sustainably delivered. ERP transition was messier than promised. Litter and Glad losing share for 6+ quarters. Top-line execution is the chronic weakness.

Gate result: One MIXED and two PARTIAL gates. Score normally but note the gaps. The margin recovery story is genuine and the cost discipline is strong, but management has not proven it can deliver consistent organic revenue growth. The ERP disruption, while temporary, revealed execution gaps despite years of planning and a Canada pilot.

Score breakdown

/ 10

Financial Trends Weight: 25%

Revenue has gone nowhere in 5 years: FY2021 $7.3B vs FY2025 $7.1B. FY2026 H1 sharply deteriorating: organic sales -17% and -1%, gross margins contracting YoY (-410bps in FQ1), EBIT margins collapsing to 11.2% in FQ1, GAAP EPS declining double digits. The multi-year margin recovery from 35.8% to 45.2% gross margin (FY22-FY25) was genuinely impressive, but 3 of 4 segments declining organically. ERP transition masking underlying weakness.

/ 10

Thematic Exposure Weight: 25%

Dominant market positions (#1 or #2 in 80%+ of revenue) across household staples -- Kingsford ~80% charcoal, Clorox ~60% bleach, Glad #1-2 in trash bags. But these positions sit in mature, low-growth categories with 0-1% underlying growth vs 2-2.5% historical. Zero exposure to secular growth themes. Share losses in Glad and Fresh Step with elevated promotions. Purell acquisition adds health/hygiene vector but does not change the fundamental profile.

/ 10

Management Quality Weight: 20%

CEO Linda Rendle delivered the #1 financial promise: gross margin rebuild from 35.8% to 45.2%. Cost savings flywheel generates 150-200+ bps annually. Portfolio pruning (Argentina, VMS divestitures) was sensible. But IGNITE 3-5% organic growth algorithm never sustainably delivered. ERP transition caused ~3 pts of out-of-stocks despite planning. Litter and Glad losing share for 6+ quarters. Candid communicator but execution inconsistent on top line.

/ 10

Investor Sentiment Weight: 15%

Deeply negative Street sentiment: only 1 of 16 analysts has a Buy, consensus is Reduce. Deutsche Bank and TD Cowen cutting targets toward/below current price. RSI 31.8 approaching oversold. Down 33% from 52-week highs. Dividend yield 4.9% near historical highs providing income floor. P/E 16.5x well below staples sector average (~20-22x). Classic contrarian setup -- management materially more optimistic than the Street on back-half innovation.

/ 10

Concerns, Catalysts & Risks Weight: 15%

Key catalysts: FY27 ERP normalization (~$0.90 EPS add-back, high probability), GOJO/Purell integration ($800M revenue, health/hygiene growth), back-half innovation pipeline. Key risks: tariff headwinds (~$40-100M), consumer weakness with categories at 0-1% growth, Household segment EBIT margins compressed to 5.3%, GOJO leverage during transition year. Valuation at 16.5x P/E provides cushion. Risk/reward balanced at current levels.

Dimension	Score	Weight	Weighted
Financial Trends	4	25%	1.00
Thematic Exposure	4	25%	1.00
Management Quality	5	20%	1.00
Investor Sentiment	7	15%	1.05
Concerns, Catalysts & Risks	5	15%	0.75
Composite		100%	4.8

Company overview

The Clorox Company is a leading manufacturer and marketer of consumer and professional products with FY2025 revenue of $7.1 billion. The company operates four segments: Health and Wellness (Clorox bleach, Pine-Sol, CloroxPro, ~38% of revenue), Household (Glad trash bags, Kingsford charcoal, Fresh Step cat litter, ~28%), Lifestyle (Hidden Valley dressings, Brita water filtration, ~18%), and International (~16%). Headquartered in Oakland, California, with a fiscal year ending June 30.

The investment case has two competing narratives. The bull case centers on a genuinely impressive multi-year margin recovery (gross margin from 35.8% in FY2022 to 45.2% in FY2025), approaching oversold technicals (RSI 31.8, down 33% from highs), a 4.9% dividend yield near historical highs, and a mechanical FY2027 EPS tailwind of ~$0.90 as ERP transition distortions reverse. The GOJO/Purell acquisition adds a growth vector in health and hygiene. Only 1 of 16 analysts has a Buy rating, creating asymmetric upside potential if the back-half innovation pipeline delivers.

The bear case is that this is a zero-growth business in structurally challenged categories. Revenue is lower today than 5 years ago. The 3-5% IGNITE organic growth algorithm has never been sustainably delivered. Categories are growing 0-1% vs the 2-2.5% historical norm. Three of four segments are declining organically. Private label pressure is persistent in commodity-adjacent categories like bleach and trash bags. The ERP transition was messier than management promised, and the back-half innovation pipeline remains unproven. Tariff headwinds of $40-100M add incremental risk.

Price	$101.14	FY2025 Revenue	$7.1B (+0.2% YoY)
Market Cap	$12.2B	Adj. EBIT Margin (FY25)	18.5% (+370bps from FY22)
Trailing P/E	16.5x	Gross Margin (FY25)	45.2% (recovered from 35.8%)
Dividend Yield	4.90%	GAAP EPS (TTM)	$6.13
52-Week Range	$96.66 - $150.84	FCF (FY2025)	$761M (10.7% of sales)
RSI	31.79	FY2026 Organic Sales Guide	-5% to -9% (incl ~7.5pts ERP)

Summary thesis

CLX receives a composite score of 4.8/10, reflecting weak financial trends (4) and thematic exposure (4) in mature, low-growth categories, offset partially by a strong contrarian sentiment signal (7) and middling management (5) and risk (5) scores. The score falls below the 6.0 threshold for a constructive view.

Bull case (~$130-140, +30-35%): FY27 EPS normalizes to ~$7.00+ as the $0.90 ERP drag reverses and GOJO adds ~$0.20-0.30. Gross margin recovers toward 45%+ as ERP costs fade and cost savings accelerate. Back-half innovation pipeline drives category and share recovery. P/E re-rates toward 18-20x on improved growth visibility. The 4.9% yield provides a floor near oversold levels.

Base case (~$110-120, +10-20%): FY26 EPS comes in at the low end of guidance (~$5.95 adj.). FY27 EPS recovers to ~$6.80-7.00 on ERP normalization plus GOJO contribution. Gross margins stabilize with moderate innovation traction. Categories remain flat to +1%. P/E ~17x on FY27 estimates implies ~$115-120.

Bear case (~$80-85, -15-20%): Tariffs escalate beyond $100M. Consumer recession deepens with category growth stalling at 0%. GOJO integration stumbles while adding leverage during a transition year. Household segment (Glad, Litter) continues share bleed despite innovation. P/E compresses to 13-14x on earnings misses.

Bottom line: Clorox is a fundamentally sound franchise going through a trough in both earnings and sentiment. The contrarian setup is real -- deeply negative analyst consensus, approaching oversold technicals, and a near-5% dividend yield historically act as a floor. But the core problem is structural: this is a zero-growth top line in categories with 0-1% underlying growth, and the IGNITE growth algorithm has never been sustainably delivered. The FY27 ERP normalization is mechanical, not organic. AVOID / Watchlist, and monitor for evidence that (1) back-half innovation translates to share recovery and (2) categories re-accelerate above 1%. Either signal would warrant a re-evaluation.

What to watch

Key catalysts and monitoring points:

Q3 FY2026 earnings (~May 2026): Watch for back-half innovation traction -- shelf resets for the allergen platform, Glad Leakguard, and litter relaunch hit in Q3/Q4. Any evidence of share recovery in Glad or Fresh Step would be a meaningful positive.
GOJO/Purell integration (completed Apr 2026): $800M revenue business in health and hygiene. Monitor for integration execution and whether it drives Health and Wellness segment acceleration. Management sees mid-single-digit growth CAGR.
ERP transition completion (Q3 FY2026): The five-year digital transformation completes this quarter. Watch for ERP-related costs to dissipate and S&A to start moving toward the 13% of sales target (currently 15-16%).
Category growth trajectory: Currently running 0-1% vs the 2-2.5% historical norm that underpins the IGNITE algorithm. Consumer spending on household essentials is a leading indicator of whether the organic growth algorithm is achievable.
Tariff evolution: ~$40M guided for FY2026, potentially $100M+ annualized. Clorox manufactures close to where it sells (relatively low exposure), but resin, packaging, and raw materials carry tariff risk. Management is exploring sourcing changes.
Gross margin in Q3-Q4 FY2026: Management guided to expansion in the back half as ERP costs fade, Glad JV termination adds ~50bps, and cost savings ramp. Confirmation would support the FY27 earnings recovery narrative.
Dividend sustainability: 4.9% yield on $761M FCF is well covered today, but FY2026 FCF is tracking weaker. Monitor for any signal of dividend pressure.

For the full analysis, see the Financials, Thematics, and Management pages.

Data sourced from Daloopa (company_id: 332) and CLX earnings transcripts (FQ1 FY2026, FQ2 FY2026, FQ4 FY2025).